Influenza virus resistance to oseltamivir: What are the implications

European Journal of Public Health

Volumn 19, Issue 3, 2009, Pages 238-239

  Fleming, Douglas M ^a   Elliot, Alex J ^a   Meijer, Adam ^b   Paget, W John ^c  

^a ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AVIAN INFLUENZA; GENE MUTATION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H1N1 INFECTION; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; DISASTER PLANNING; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; OSELTAMIVIR;

EID: 66249138849     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckp012     Document Type: Short Survey

References (13)

1. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008;13. Available at: http://www.eurosurveillance.org/edition/v13n05/ 080131-2.asp (Accessed 9 January 2009).
2. Centers for Disease Control and Prevention. Update: influenza activity-United States, September 28-November 29. 2008. MMWR Morb Mortal Wkly Rep 2008;57:1329-32.
3. European Influenza Surveillance Scheme (EISS): EISS Weekly Electronic Bulletin. Available at: http://www.eiss.org/cgi-files/bulletin-v2.cgi (Accessed 9 January 2009).
4. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006;50:2395-402.
5. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008;52:3284-92.
6. Neuraminidase Inhibitor Susceptibility Network. Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance. Wkly Epidemiol Rec 2005;80:156.
7. Neuraminidase Inhibitor Susceptibility Network. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly Epidemiol Rec 2007;82:149-50.
8. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008;21:626-38.
9. van der Vries E, Wensing AMJ, Schutten M, et al. Two fatal oseltamivir resistant influenza A (H1N1) infections in immunocompromised patients during the 2007/2008 influenza season in the Netherlands. The Third European Influenza Conference. Vilamoura, Portugal: European Scientific Working Group on Influenza, 2008.
10. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006;70:121-31.
11. Fleming DM, Moult AB, Keene O. Indicators and significance of severity in influenza patients. Int Congr Ser 2001;1219:637-43.
12. Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004;363:587-93.
13. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-72.